Low dose lenalidomide induction followed by autologous transplantation in untreated patients with myeloma is associated with adequate collection of haematopoietic and dendritic cell precursors and high response rates

      Lenalidomide 25 mg D1-21 with dexamethasone 40 mg weekly is effective in first line and maintenance treatment of myeloma. Higher doses of lenalidomide and dexamethasone are associated with increased toxicity. We examined efficacy of low dose lenalidomide and dexamethasone induction followed by consolidation haematopoietic stem cell Transplantation HSCT in LITVacc, a phase II study of Lenalidomide Induction, HSCT and adjuvant Vaccination with autologous dendritic cells (DC) loaded with autologous tumour cell lysate (ATCL) and lenalidomide maintenance.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect